CRUZ Tunisia-Multivessel Registry

Recruiting Observational Study
Patient Population With Multivessel Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 99
Sex
Any
Study type
Observational
Participants needed
1,000 (estimated)
Sponsor
Sahajanand Medical Technologies Limited · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

The primary objective of this registry is to evaluate the safety and clinical performance of the biodegradable polymer-coated Supraflex Cruz Sirolimus-eluting Stent (SES) in an unselected, all-comer patient population with multivessel disease. This population represents daily clinical practice and includes patients requiring coronary revascularization with drug-eluting stents (DES).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Patient must be at least 18 years of age 2. Patients with symptomatic coronary artery multivessel disease requiring the implantation of at least two Supraflex Cruz stents into the coronary vasculature during the index procedure 3. The patient, or legal representative, has bee…
Contacts

Prof. Nadhem HAJLAOUI

+216 55130873

drnadhemhajlaoui@gmail.com

CONTACT